Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? Against

被引：28
作者：
Goldenberg, DM
Sharkey, RM
Karacay, H
Goldenberg, DM
McBride, W
Hansen, HJ
Goldenberg, DM
Chang, CH
Rossi, EA
Chatal, JF
Barbet, J
机构：
[1] Garden State Canc Ctr, Ctr Mol Med & Immunol, Belleville, NJ 07109 USA
[2] Immunomed Inc, Morris Plains, NJ USA
[3] IBC Pharmaceut Inc, Morris Plains, NJ USA
[4] Ctr Rene Gauducheau, F-44035 Nantes, France
[5] INSERM, U463, Nantes, France
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2003年 / 30卷 / 05期
关键词：
D O I：
10.1007/s00259-002-1089-6
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：776 / 780
页数：5
相关论文
共 35 条
[1]   Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity [J].
Axworthy, DB ;
Reno, JM ;
Hylarides, MD ;
Mallett, RW ;
Theodore, LJ ;
Gustavson, LM ;
Su, FM ;
Hobson, LJ ;
Beaumier, PL ;
Fritzberg, AR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (04) :1802-1807
[2]   Developments with targeted enzymes in cancer therapy [J].
Bagshawe, KD ;
Sharma, SK ;
Burke, PJ ;
Melton, RG ;
Knox, RJ .
CURRENT OPINION IN IMMUNOLOGY, 1999, 11 (05) :579-583
[3]   Pretargeting with the Affinity Enhancement System for radioimmunotherapy [J].
Barbet, J ;
Kraeber-Bodéré, F ;
Vuillez, JP ;
Gautherot, E ;
Rouvier, R ;
Chatal, JF .
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (03) :153-166
[4]  
Chang CH, 2002, MOL CANCER THER, V1, P553
[5]   BIFUNCTIONAL ANTIBODIES FOR RADIOIMMUNOTHERAPY [J].
CHATAL, JF ;
FAIVRECHAUVET, A ;
BARDIES, M ;
PELTIER, P ;
GAUTHEROT, E ;
BARBET, J .
HYBRIDOMA, 1995, 14 (02) :125-128
[6]  
Fritzberg AR, 1998, J NUCL MED, V39, p20N
[7]  
Gautherot E, 2000, J NUCL MED, V41, P480
[8]  
Goldenberg DM, 2002, J NUCL MED, V43, P693
[9]  
Goldenberg DM, 2001, CRIT REV ONCOL HEMAT, V39, P195
[10]  
GOODWIN DA, 1988, J NUCL MED, V29, P226
1234